Cancer Treatment Method
Disclosed herein is a method of treating breast cancer that has metastasized to the brain in a mammal by administration of 4-quinazolinamines and pharmaceutical compositions containing the same. In particular, the method relates to methods of treating breast cancer brain metastases which overexpress erbB2 by administration of N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine and salts and solvates thereof.
1 - 9 . (canceled)
10 . A method of treating breast cancer metastases in the brain of a mammal, comprising: administering to said mammal a therapeutically effective amount of a compound of formula (I)
or salts or solvates thereof.
11 . The method of claim 10 , wherein the breast cancer brain metastases overexpress erbB-2.
12 . A method of treating breast cancer metastases in the brain of a mammal, comprising: administering to said mammal a therapeutically effective amount of a compound of formula (I′)
or solvates thereof.
13 . The method of claim 12 , wherein the breast cancer brain metastases overexpress erbB-2.
14 . A method of treating breast cancer metastases in the brain of a mammal, comprising: administering to said mammal a therapeutically effective amount of a compound of formula (I″).
15 . The method of claim 14 , wherein the breast cancer brain metastases overexpress erbB-2.
16 - 21 . (canceled)
22 . The method of claim 10 , wherein the mammal has previously been treated with trastuzumab.
23 . The method of claim 10 , further comprising administering a therapeutically effective amount of at least one additional cancer treatment therapy.
24 . The method of claim 23 , wherein the at least one additional cancer treatment therapy is radiation therapy.
25 . The method of claim 24 , wherein the radiation therapy is stereotactic radiosurgery.
26 . The method of claim 24 , wherein the radiation therapy is whole brain radiotherapy.
27 . The method of claim 23 , wherein the at least one additional cancer treatment therapy is administration of at least one anti-neoplastic agent.
28 . The method of claim 27 , wherein the at least one anti-neoplastic agent is a fluoropyrimidine.
29 . The method of claim 28 , wherein the fluoropyrimidine is 5-fluorouracil.
30 . The method of claim 29 , wherein the at least one anti-neoplastic agent is an inhibitor of a VEGFR.
31 . The method of claim 10 , further comprising administering a therapeutically effective amount of elacridar.
32 . The method of claim 12 , wherein the mammal has previously been treated with trastuzumab.
33 . The method of claim 12 , further comprising administering a therapeutically effective amount of at least one additional cancer treatment therapy.
34 . The method of claim 33 , wherein the at least one additional cancer treatment therapy is radiation therapy.
35 . The method of claim 34 , wherein the radiation therapy is stereotactic radiosurgery.
36 . The method of claim 34 , wherein the radiation therapy is whole brain radiotherapy.
37 . The method of claim 33 , wherein the at least one additional cancer treatment therapy is administration of at least one anti-neoplastic agent.
38 . The method of claim 37 , wherein the at least one anti-neoplastic agent is a fluoropyrimidine.
39 . The method of claim 38 , wherein the fluoropyrimidine is 5-fluorouracil.
40 . The method of claim 37 , wherein the at least one anti-neoplastic agent is an inhibitor of a VEGFR.
41 . The method of claim 12 , further comprising administering a therapeutically effective amount of elacridar.
42 . The method of claim 14 , wherein the mammal has previously been treated with trastuzumab.
43 . The method of claim 14 , further comprising administering a therapeutically effective amount of at least one additional cancer treatment therapy.
44 . The method of claim 43 , wherein the at least one additional cancer treatment therapy is radiation therapy.
45 . The method of claim 44 , wherein the radiation therapy is stereotactic radiosurgery.
46 . The method of claim 44 , wherein the radiation therapy is whole brain radiotherapy.
47 . The method of claim 43 , wherein the at least one additional cancer treatment therapy is administration of at least one anti-neoplastic agent.
48 . The method of claim 47 , wherein the at least one anti-neoplastic agent is a fluoropyrimidine.
49 . The method of claim 48 , wherein the fluoropyrimidine is 5-fluorouracil.
50 . The method of claim 47 , wherein the at least one anti-neoplastic agent is an inhibitor of a VEGFR.
51 . The method of claim 14 , further comprising administering a therapeutically effective amount of elacridar.